We would like to advise list member of an upcoming seminar by John Whittaker, GSK at the University of Liverpool (Nicholson Lecture Theatre) at 5pm on 26th January 2012:
Genetics in drug discovery and development
John Whittaker,Vice President, Statistical Platforms and Technologies, Qsci,GlaxoSmithKline, Medicines Research Centre.
There are a number of possible uses of genetics to support drug discovery and development. Most obviously, we discuss pharmacogenetics, that is the investigation of genetic variants that contribute to variation in the risk of drug related adverse events or the efficacy of medicines, using examples from recent GSK oncology projects.
In addition, genetics may provide information to support intervention on particular targets, and hence increase the reason to believe that certain medicines might be effective against particular indications, or suggest new indications for existing medicines. In this context we describe a recent GSK project based on second generation sequencing of 202 genes encoding GSK drug targets in 15000 individuals across a number of diseases. We discuss the data quality and summarise the variation found, before giving some initial results on gene phenotype associations and summarising the implications for future large scale sequence based association studies.
A brief introduction to genetics will be included for those not familiar with the area, and technical details, both genetic and statistical will be avoided wherever possible throughout.
Further details available at: http://www.liv.ac.uk/events/event.php?event_id=31590&event_day_id=48964
You may leave the list at any time by sending the command
SIGNOFF allstat
to [log in to unmask], leaving the subject line blank.
|